OUR LATEST INVESTOR INFORMATION
Crystal Research Associates Executive Informational Overview, March 10, 2022
Download PDF
Competitive Advantage / VALUE PROPOSITION

World-Class Pipeline

Neurodegenerative and neuropsychiatric disease, multi-billion dollar markets, unmet need, decades of research de-risk our drugs
Lucid-MS: New Chemical Entity for Multiple Sclerosis, pre-clinical research re-established use of paralyzed rear legs in MS mouse model, research published in peer-reviewed journals, Filing for IND with FDA for phase-1 clinical trials targeted for Q4 2022
FSD201: Proprietary ultra-micro PEA (palmitoylethanolamide) compound, solid safety profile in humans, Phase 2 clinical trials for inflammatory disease targeted Q4 2022
Lucid-Psych: Novel pathway (unique MOA) to treat Major Depressive Disorder, Filing for IND with FDA for phase-1 clinical trials targeted for Q4 2022
IP Estate: FSD Pharma has rights to patent families licensed on an exclusive basis

Elite Team

FSD Pharma’s flagship subsidiary led by Dr. Lakshmi Kotra, the recipient of the Julia Levy Award and a senior scientist at the Krembil Brain Institute, as well as the world-renowned University Health Network (UHN).
FSD Pharma has 6 PhD’s and 2 MD’s working full-time on pipeline development, with backgrounds at the FDA, major pharmaceuticals firms, and esteemed universities.
FSD Pharma team includes 2 Julia Levy Award recipients, a distinguished award that has only been awarded to 8 recipients since its inception in 2005 (no other company can make this claim)

Strong Cash Position

Cash significant for operations (including 3 planned clinical trials)
No dilution on horizon for shareholders

Solid Cap Table / Insider Ownership

Only 38.1 million shares issued
Share repurchase plan ongoing, approximately 2 million shares returned to treasury in 2022
Co-founders Zeeshan Saeed and Anthony Durkacz and other insiders frequently buying shares since start of 2022 and continue to accumulate shares. These holdings can be verified by checking the SEDI filings



*Data current as of May 20, 2022

Industry classifications

Sector:

Healthcare

Industry:

Drug Manufacturers

NAICS:

Pharmaceutical
Preparation
Manufacturing (325412)

SIC:

Pharmaceutical and
Medicine Industry
(3741)

Stock data
Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
RT=Real-Time, EOD=End of Day, PD=Previous Day.
Market Data powered by QuoteMedia. Terms of Use.
Financial results
FY 2018

FISCAL YEAR ENDED DEC 31, 2018

Earnings Release
Q3 2018

QUARTER ENDED SEP 30, 2018

Earnings Release
Q2 2018

QUARTER ENDED JUN 30, 2018

Earnings Release
SEC filling
Latest quarterly or annual filing
Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

DECEMBER 31, 2021
20-F
Latest current report
Condensed consolidated interim financial statements for the three months ended March 31, 2022, and 2021

MAY 13, 2022
PDF
PDF
Company Structure
Our leadership consists of a passionate management team with diverse industry knowledge, committed to science, therapeutic drug discovery and development.
BOARD OF DIRECTORS
...
EXPERT RESEARCH AND CLINICAL TEAM
...
MANAGEMENT TEAM
...
REGULATORY ADVISORY BOARD
...
Governance Documents
CODE OF CONDUCT AND ETHICS PDF
NASDAQ CORPORATE GOVERNANCE DISCLOSURE STATEMENT PDF
FAQ
  • What is FSD Pharma Inc.'s stock symbol?

    Our stock is traded on the CSE under the symbol HUGE and on the Nasdaq under the symbol HUGE
  • When was FSD Pharma Inc. incorporated?

    November 1, 1998
  • When did FSD Pharma Inc. become a public company?

    May 29, 2018
  • When is FSD Pharma Inc.'s fiscal year end?

    December 31st
  • Who is FSD Pharma Inc.'s transfer agent?

    Marrelli Support Services Inc. (MSSI)
  • Who is FSD Pharma Inc.'s independent auditor?

    MNP LLP
  • Who is FSD Pharma Inc.'s outside legal counsel?

    Blake, Cassels & Graydon LL

Receive most valuable updates straight into your inbox

SIGN UP TODAY



PLEASE SEND INVESTOR INQUIRIES TO [email protected]

ALL OTHER INQUIRIES PLEASE EMAIL [email protected]

JOIN OUR TEAM

Careers

    Email Alerts

    Please fill out the form below to receive company press releases via email when they occur.


    Contact




      PLEASE SEND INVESTOR INQUIRIES TO [email protected]


      ALL OTHER INQUIRIES PLEASE EMAIL TO [email protected]




      TOP